9,600 research outputs found
Systems biology in animal sciences
Systems biology is a rapidly expanding field of research and is applied in a number of biological disciplines. In animal sciences, omics approaches are increasingly used, yielding vast amounts of data, but systems biology approaches to extract understanding from these data of biological processes and animal traits are not yet frequently used. This paper aims to explain what systems biology is and which areas of animal sciences could benefit from systems biology approaches. Systems biology aims to understand whole biological systems working as a unit, rather than investigating their individual components. Therefore, systems biology can be considered a holistic approach, as opposed to reductionism. The recently developed âomicsâ technologies enable biological sciences to characterize the molecular components of life with ever increasing speed, yielding vast amounts of data. However, biological functions do not follow from the simple addition of the properties of system components, but rather arise from the dynamic interactions of these components. Systems biology combines statistics, bioinformatics and mathematical modeling to integrate and analyze large amounts of data in order to extract a better understanding of the biology from these huge data sets and to predict the behavior of biological systems. A âsystemâ approach and mathematical modeling in biological sciences are not new in itself, as they were used in biochemistry, physiology and genetics long before the name systems biology was coined. However, the present combination of mass biological data and of computational and modeling tools is unprecedented and truly represents a major paradigm shift in biology. Significant advances have been made using systems biology approaches, especially in the field of bacterial and eukaryotic cells and in human medicine. Similarly, progress is being made with âsystem approachesâ in animal sciences, providing exciting opportunities to predict and modulate animal traits
Systems analysis of drug-induced receptor tyrosine kinase reprogramming following targeted mono- and combination anti-cancer therapy
The receptor tyrosine kinases (RTKs) are key drivers of cancer progression and targets for drug therapy. A major challenge in anti-RTK treatment is the dependence of drug effectiveness on co-expression of multiple RTKs which defines resistance to single drug therapy. Reprogramming of the RTK network leading to alteration in RTK co-expression in response to drug intervention is a dynamic mechanism of acquired resistance to single drug therapy in many cancers. One route to overcome this resistance is combination therapy. We describe the results of a joint in silico, in vitro, and in vivo investigations on the efficacy of trastuzumab, pertuzumab and their combination to target the HER2 receptors. Computational modelling revealed that these two drugs alone and in combination differentially suppressed RTK network activation depending on RTK co-expression. Analyses of mRNA expression in SKOV3 ovarian tumour xenograft showed up-regulation of HER3 following treatment. Considering this in a computational model revealed that HER3 up-regulation reprograms RTK kinetics from HER2 homodimerisation to HER3/HER2 heterodimerisation. The results showed synergy of the trastuzumab and pertuzumab combination treatment of the HER2 overexpressing tumour can be due to an independence of the combination effect on HER3/HER2 composition when it changes due to drug-induced RTK reprogramming
Integrated signaling pathway and gene expression regulatory model to dissect dynamics of <em>Escherichia coli </em>challenged mammary epithelial cells
AbstractCells transform external stimuli, through the activation of signaling pathways, which in turn activate gene regulatory networks, in gene expression. As more omics data are generated from experiments, eliciting the integrated relationship between the external stimuli, the signaling process in the cell and the subsequent gene expression is a major challenge in systems biology. The complex system of non-linear dynamic protein interactions in signaling pathways and gene networks regulates gene expression.The complexity and non-linear aspects have resulted in the study of the signaling pathway or the gene network regulation in isolation. However, this limits the analysis of the interaction between the two components and the identification of the source of the mechanism differentiating the gene expression profiles. Here, we present a study of a model of the combined signaling pathway and gene network to highlight the importance of integrated modeling.Based on the experimental findings we developed a compartmental model and conducted several simulation experiments. The model simulates the mRNA expression of three different cytokines (RANTES, IL8 and TNFα) regulated by the transcription factor NFÎșB in mammary epithelial cells challenged with E. coli. The analysis of the gene network regulation identifies a lack of robustness and therefore sensitivity for the transcription factor regulation. However, analysis of the integrated signaling and gene network regulation model reveals distinctly different underlying mechanisms in the signaling pathway responsible for the variation between the three cytokine's mRNA expression levels. Our key findings reveal the importance of integrating the signaling pathway and gene expression dynamics in modeling. Modeling infers valid research questions which need to be verified experimentally and can assist in the design of future biological experiments
Reverse engineering of drug induced DNA damage response signalling pathway reveals dual outcomes of ATM kinase inhibition
The DNA Damage Response (DDR) pathway represents a signalling mechanism that is activated in eukaryotic cells following DNA damage and comprises of proteins involved in DNA damage detection, DNA repair, cell cycle arrest and apoptosis. This pathway consists of an intricate network of signalling interactions driving the cellular ability to recognise DNA damage and recruit specialised proteins to take decisions between DNA repair or apoptosis. ATM and ATR are central components of the DDR pathway. The activities of these kinases are vital in DNA damage induced phosphorylational induction of DDR substrates. Here, firstly we have experimentally determined DDR signalling network surrounding the ATM/ATR pathway induced following double stranded DNA damage by monitoring and quantifying time dependent inductions of their phosphorylated forms and their key substrates. We next involved an automated inference of unsupervised predictive models of time series data to generate in silico (molecular) interaction maps. We characterized the complex signalling network through system analysis and gradual utilisation of small time series measurements of key substrates through a novel network inference algorithm. Furthermore, we demonstrate an application of an assumption-free reverse engineering of the intricate signalling network of the activated ATM/ATR pathway. We next studied the consequences of such drug induced inductions as well as of time dependent ATM kinase inhibition on cell survival through further biological experiments. Intermediate and temporal modelling outcomes revealed the distinct signaling profile associated with ATM kinase activity and inhibition and explained the underlying signalling mechanism for dual ATM functionality in cytotoxic and cytoprotective pathways
Simulating non-small cell lung cancer with a multiscale agent-based model
Background The epidermal growth factor receptor (EGFR) is frequently
overexpressed in many cancers, including non-small cell lung cancer (NSCLC). In
silcio modeling is considered to be an increasingly promising tool to add
useful insights into the dynamics of the EGFR signal transduction pathway.
However, most of the previous modeling work focused on the molecular or the
cellular level only, neglecting the crucial feedback between these scales as
well as the interaction with the heterogeneous biochemical microenvironment.
Results We developed a multiscale model for investigating expansion dynamics
of NSCLC within a two-dimensional in silico microenvironment. At the molecular
level, a specific EGFR-ERK intracellular signal transduction pathway was
implemented. Dynamical alterations of these molecules were used to trigger
phenotypic changes at the cellular level. Examining the relationship between
extrinsic ligand concentrations, intrinsic molecular profiles and microscopic
patterns, the results confirmed that increasing the amount of available growth
factor leads to a spatially more aggressive cancer system. Moreover, for the
cell closest to nutrient abundance, a phase-transition emerges where a minimal
increase in extrinsic ligand abolishes the proliferative phenotype altogether.
Conclusions Our in silico results indicate that, in NSCLC, in the presence of
a strong extrinsic chemotactic stimulus, and depending on the cell's location,
downstream EGFR-ERK signaling may be processed more efficiently, thereby
yielding a migration-dominant cell phenotype and overall, an accelerated
spatio-temporal expansion rate.Comment: 37 pages, 7 figure
Addressing current challenges in cancer immunotherapy with mathematical and computational modeling
The goal of cancer immunotherapy is to boost a patient's immune response to a
tumor. Yet, the design of an effective immunotherapy is complicated by various
factors, including a potentially immunosuppressive tumor microenvironment,
immune-modulating effects of conventional treatments, and therapy-related
toxicities. These complexities can be incorporated into mathematical and
computational models of cancer immunotherapy that can then be used to aid in
rational therapy design. In this review, we survey modeling approaches under
the umbrella of the major challenges facing immunotherapy development, which
encompass tumor classification, optimal treatment scheduling, and combination
therapy design. Although overlapping, each challenge has presented unique
opportunities for modelers to make contributions using analytical and numerical
analysis of model outcomes, as well as optimization algorithms. We discuss
several examples of models that have grown in complexity as more biological
information has become available, showcasing how model development is a dynamic
process interlinked with the rapid advances in tumor-immune biology. We
conclude the review with recommendations for modelers both with respect to
methodology and biological direction that might help keep modelers at the
forefront of cancer immunotherapy development.Comment: Accepted for publication in the Journal of the Royal Society
Interfac
Connecting Cancer Pathways to Tumor Engines: A Stratification Tool for Colorectal Cancer Combining Human In Vitro Tissue Models with Boolean In Silico Models
To improve and focus preclinical testing, we combine tumor models based on a decellularized tissue matrix with bioinformatics to stratify tumors according to stage-specific mutations that are linked to central cancer pathways. We generated tissue models with BRAF-mutant colorectal cancer (CRC) cells (HROC24 and HROC87) and compared treatment responses to two-dimensional (2D) cultures and xenografts. As the BRAF inhibitor vemurafenib isâin contrast to melanomaânot effective in CRC, we combined it with the EGFR inhibitor gefitinib. In general, our 3D models showed higher chemoresistance and in contrast to 2D a more active HGFR after gefitinib and combination-therapy. In xenograft models murine HGF could not activate the human HGFR, stressing the importance of the human microenvironment. In order to stratify patient groups for targeted treatment options in CRC, an in silico topology with different stages including mutations and changes in common signaling pathways was developed. We applied the established topology for in silico simulations to predict new therapeutic options for BRAF-mutated CRC patients in advanced stages. Our in silico tool connects genome information with a deeper understanding of tumor engines in clinically relevant signaling networks which goes beyond the consideration of single drivers to improve CRC patient stratification
Engineering simulations for cancer systems biology
Computer simulation can be used to inform in vivo and in vitro experimentation, enabling rapid, low-cost hypothesis generation and directing experimental design in order to test those hypotheses. In this way, in silico models become a scientific instrument for investigation, and so should be developed to high standards, be carefully calibrated and their findings presented in such that they may be reproduced. Here, we outline a framework that supports developing simulations as scientific instruments, and we select cancer systems biology as an exemplar domain, with a particular focus on cellular signalling models. We consider the challenges of lack of data, incomplete knowledge and modelling in the context of a rapidly changing knowledge base. Our framework comprises a process to clearly separate scientific and engineering concerns in model and simulation development, and an argumentation approach to documenting models for rigorous way of recording assumptions and knowledge gaps. We propose interactive, dynamic visualisation tools to enable the biological community to interact with cellular signalling models directly for experimental design. There is a mismatch in scale between these cellular models and tissue structures that are affected by tumours, and bridging this gap requires substantial computational resource. We present concurrent programming as a technology to link scales without losing important details through model simplification. We discuss the value of combining this technology, interactive visualisation, argumentation and model separation to support development of multi-scale models that represent biologically plausible cells arranged in biologically plausible structures that model cell behaviour, interactions and response to therapeutic interventions
Bridging scales in cancer progression: Mapping genotype to phenotype using neural networks
In this review we summarize our recent efforts in trying to understand the
role of heterogeneity in cancer progression by using neural networks to
characterise different aspects of the mapping from a cancer cells genotype and
environment to its phenotype. Our central premise is that cancer is an evolving
system subject to mutation and selection, and the primary conduit for these
processes to occur is the cancer cell whose behaviour is regulated on multiple
biological scales. The selection pressure is mainly driven by the
microenvironment that the tumour is growing in and this acts directly upon the
cell phenotype. In turn, the phenotype is driven by the intracellular pathways
that are regulated by the genotype. Integrating all of these processes is a
massive undertaking and requires bridging many biological scales (i.e.
genotype, pathway, phenotype and environment) that we will only scratch the
surface of in this review. We will focus on models that use neural networks as
a means of connecting these different biological scales, since they allow us to
easily create heterogeneity for selection to act upon and importantly this
heterogeneity can be implemented at different biological scales. More
specifically, we consider three different neural networks that bridge different
aspects of these scales and the dialogue with the micro-environment, (i) the
impact of the micro-environment on evolutionary dynamics, (ii) the mapping from
genotype to phenotype under drug-induced perturbations and (iii) pathway
activity in both normal and cancer cells under different micro-environmental
conditions
Key environmental stress biomarker candidates for the optimisation of chemotherapy treatment of leukaemia
The impact of fluctuations of environmental parameters
such as oxygen and starvation on the evolution of leukaemia
is analysed in the current review. These fluctuations may occur
within a specific patient (in different organs) or across patients
(individual cases of hypoglycaemia and hyperglycaemia). They
can be experienced as stress stimuli by the cancerous population,
leading to an alteration of cellular growth kinetics, metabolism
and further resistance to chemotherapy. Therefore, it is of high
importance to elucidate key mechanisms that affect the evolution
of leukaemia under stress. Potential stress response mechanisms
are discussed in this review. Moreover, appropriate cell biomarker
candidates related to the environmental stress response and/or
further resistance to chemotherapy are proposed. Quantification
of these biomarkers can enable the combination of macroscopic kinetics
with microscopic information, which is specific to individual
patients and leads to the construction of detailed mathematical
models for the optimisation of chemotherapy. Due to their nature,
these models will be more accurate and precise (in comparison
to available macroscopic/black box models) in the prediction of
responses of individual patients to treatment, as they will incorporate
microscopic genetic and/or metabolic information which is
patient-specific.peer-reviewe
- âŠ